NSE: SUPRIYA | BSE: 543434

Mid-range Performer

Download real time

662.25 -27.30 (-3.96%)

29.50% Gain from 52W Low

202.8K NSE+BSE Volume

NSE 25 Aug, 2025 3:53 PM (IST)

5,330

Market Cap

Above industry Median

1.9

Beta 1Year

Very High Volatility

Supriya Lifescience Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUPRIYA, BSE:543434 Supriya Lifescience Ltd.

Search Inside the pdf :

Supriya Lifescience Ltd.

22 Aug 2025

662.25

-3.96%

Short-term weakness; robust pipeline supports outlook

Buy: Supriya Lifescience Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -3.8%/+0.3% primarily to reflect miss in the Q1FY26 performance, and higher depreciation expenses, however, FY27 numbers are intact with rising regulated market share, enhanced backward integration, scale-up of the DSM contract, and new launches such as contrast media and ADHD APIs.

Supriya Lifescience Ltd.'s price crossed below 30Day SMA today

Supriya Lifescience Ltd.

22 Dec 2023

662.25

-3.96%

Pick of the Day (Short Term Delivery Call)

Accumulate: Supriya Lifescience Ltd.

SBI Securities

SLL has a niche product basket of 38 APIs with presence in therapeutic areas of Analgesics, Anti-histamine, vitamins, anti-asthmatics, anti-allergic and anti-malarial. The company has tied up with
Kalinga Institute of Technology for development of GelHeal and Quickblue Oral Kit.

Supriya Lifescience Ltd.'s price crossed below 30Day SMA today

Supriya Lifescience Ltd.

16 Dec 2021

662.25

-3.96%

SUPRIYA LIFESCIENCES LTD.

IPO Note: Supriya Lifescience Ltd.

Hem Securities

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. As of October 31, 2021, company have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic,...

Supriya Lifescience Ltd. is trading below all available SMAs

Supriya Lifescience Ltd.

16 Dec 2021

662.25

-3.96%

Supriya Lifescience : IPO

IPO Note: Supriya Lifescience Ltd.

ICICI Securities Limited

Supriya has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between FY17 and FY21. SLL is among the largest exporters of Salbutamol Sulphate in India contributing to...

Deven Choksey released a Buy report for Supriya Lifescience Ltd. with a price target of 800.0 on 22 Aug, 2025.

Supriya Lifescience Ltd.

15 Dec 2021

662.25

-3.96%

Supriya Lifescience Ltd

IPO Subscribe: Supriya Lifescience Ltd.

Angel Broking

Supriya Lifescience Limited was incorporated in March 2008 by Satish Waman Wagh. Company is one of the key Indian manufacturers and suppliers of active pharmaceutical ingredients (APIs). Supriya Lifescience Limited focus on research and development along with this company focus is on diverse therapeutic areas and niche products. Company has niche product offerings of 38

Supriya Lifescience Ltd.'s price crossed below 50Day SMA today

Supriya Lifescience Ltd.

15 Dec 2021

662.25

-3.96%

SUPRIYA LIFESCIENCE LTD.

IPO Note: Supriya Lifescience Ltd.

Ventura

IPO NOTE

Deven Choksey released a Buy report for Supriya Lifescience Ltd. with a price target of 800.0 on 22 Aug, 2025.

Supriya Lifescience Ltd.

15 Dec 2021

662.25

-3.96%

Supriya Lifescience Ltd. IPO Note

IPO Note: Supriya Lifescience Ltd.

Ashika Research

Public issue of 2,55,47,445 Equity shares of Face value Total Public 2 each, (Comprising of fresh issue of 72,99,270 Equity Shares* (Rs. 200 cr.) and Offer for Sale of 1,82,48,175 Equity Shares* (Rs. 500 cr.) by Selling Shareholder)....

Deven Choksey released a Buy report for Supriya Lifescience Ltd. with a price target of 800.0 on 22 Aug, 2025.

VOTE: Is Supriya Lifescience Ltd. worth buying?

109 Votes:

Buy 86.24%

Sell 6.42%

Hold 7.34%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf